FDA Approved: EBGLYSS — Supplemental Application (Eli Lilly and Company)

View source ↗

Summary

FDA approved a supplemental application for EBGLYSS (lebrikizumab-lbkz) from Eli Lilly, affecting the drug's label.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Atopic Dermatitis

Drugs mentioned

• EBGLYSS (LEBRIKIZUMAB-LBKZ)

Snippet

SUPPL AP for EBGLYSS (LEBRIKIZUMAB-LBKZ)